Haubrich R, Havlir D, Torriani F, Parenti D, Forthal D, Witt M, Bozzette S, Dunne M, McCutchan JA; Conference on Retroviruses and Opportunistic Infections.
Program Abstr 3rd Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 3rd 1996 Wash D C. 1996 Jan 28-Feb 1; 3rd: 158.
University of California at San Diego, Irvine, CA.
Objective: (1) To determine if D or W fluconazole alters the species or Fz susceptibility of yeast isolates colonizing the oropharynx of HIV (+) patients. (2) To determine if pre-study antifungal therapy alters fungal colonization. Methods: A subset of HIV(+) patients with CD4 less than 100 enrolled in a randomized, blinded trial of 200 mg D versus 400 mg W FZ had surveillance oropharyngeal fungal cultures at baseline and 6 months. For positive cultures, species identification and FZ MIC using the NCCLS standard assay (read at 48 hours) were determined. Results: Baseline C.albicans isolates from 12 patients with pre-study FZ use had a geometric mean (GM) MIC of .94. The number of cultures, percent positive, and GM MIC for baseline and 6-month isolates Were:(Table: See Text). Of 16 baseline/6 month pairs, 4 (2D,2W) C.albicans isolates were replaced with non-albicans. In the remaining 11 pairs (3D,8W), the GM MIC for baseline C.albicans was unchanged at 6 months. Conclusion: Treatment with either daily or weekly fluconazole reduced oropharyngeal candida colonization but the reduction was not significant in the weekly group. Although the FZ sensitivity of C.albicans strains appeared not to change, the proportion of non-albicans isolates at 6 months was higher.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- Candida
- Candidiasis
- Candidiasis, Oral
- Disease Susceptibility
- Fluconazole
- HIV Infections
- HIV Seropositivity
- Humans
- Microbial Sensitivity Tests
- Oropharynx
- Werner Syndrome
- drug therapy
- therapy
Other ID:
UI: 102216618
From Meeting Abstracts